Lost in the crowd

identifying targetable MHC class I neoepitopes for cancer immunotherapy

Eric A. Wilson, Karen Anderson

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: The recent development of checkpoint blockade immunotherapy for cancer has led to impressive clinical results across multiple tumor types. There is mounting evidence that immune recognition of tumor derived MHC class I (MHC-I) restricted epitopes bearing cancer specific mutations and alterations is a crucial mechanism in successfully triggering immune-mediated tumor rejection. Therapeutic targeting of these cancer specific epitopes (neoepitopes) is emerging as a promising opportunity for the generation of personalized cancer vaccines and adoptive T cell therapies. However, one major obstacle limiting the broader application of neoepitope based therapies is the difficulty of selecting highly immunogenic neoepitopes among the wide array of presented non-immunogenic HLA ligands derived from self-proteins. Areas covered: In this review, we present an overview of the MHC-I processing and presentation pathway, as well as highlight key areas that contribute to the complexity of the associated MHC-I peptidome. We cover recent technological advances that simplify and optimize the identification of targetable neoepitopes for cancer immunotherapeutic applications. Expert commentary: Recent advances in computational modeling, bioinformatics, and mass spectrometry are unlocking the underlying mechanisms governing antigen processing and presentation of tumor-derived neoepitopes.

Original languageEnglish (US)
Pages (from-to)1065-1077
Number of pages13
JournalExpert Review of Proteomics
Volume15
Issue number12
DOIs
StatePublished - Dec 2 2018

Fingerprint

Immunotherapy
Tumors
Epitopes
Neoplasms
Bearings (structural)
Cancer Vaccines
T-cells
Antigen Presentation
Bioinformatics
Processing
Mountings
Mass spectrometry
Ligands
Antigens
Cell- and Tissue-Based Therapy
Computational Biology
Mass Spectrometry
Proteins
T-Lymphocytes
Mutation

Keywords

  • antigen processing
  • immunotherapy
  • mass spectrometry
  • MHC
  • neoepitopes
  • peptidome
  • prediction algorithms
  • T cell

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Lost in the crowd : identifying targetable MHC class I neoepitopes for cancer immunotherapy. / Wilson, Eric A.; Anderson, Karen.

In: Expert Review of Proteomics, Vol. 15, No. 12, 02.12.2018, p. 1065-1077.

Research output: Contribution to journalReview article

@article{97e8f440971642e2a7be33a064ad0148,
title = "Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy",
abstract = "Introduction: The recent development of checkpoint blockade immunotherapy for cancer has led to impressive clinical results across multiple tumor types. There is mounting evidence that immune recognition of tumor derived MHC class I (MHC-I) restricted epitopes bearing cancer specific mutations and alterations is a crucial mechanism in successfully triggering immune-mediated tumor rejection. Therapeutic targeting of these cancer specific epitopes (neoepitopes) is emerging as a promising opportunity for the generation of personalized cancer vaccines and adoptive T cell therapies. However, one major obstacle limiting the broader application of neoepitope based therapies is the difficulty of selecting highly immunogenic neoepitopes among the wide array of presented non-immunogenic HLA ligands derived from self-proteins. Areas covered: In this review, we present an overview of the MHC-I processing and presentation pathway, as well as highlight key areas that contribute to the complexity of the associated MHC-I peptidome. We cover recent technological advances that simplify and optimize the identification of targetable neoepitopes for cancer immunotherapeutic applications. Expert commentary: Recent advances in computational modeling, bioinformatics, and mass spectrometry are unlocking the underlying mechanisms governing antigen processing and presentation of tumor-derived neoepitopes.",
keywords = "antigen processing, immunotherapy, mass spectrometry, MHC, neoepitopes, peptidome, prediction algorithms, T cell",
author = "Wilson, {Eric A.} and Karen Anderson",
year = "2018",
month = "12",
day = "2",
doi = "10.1080/14789450.2018.1545578",
language = "English (US)",
volume = "15",
pages = "1065--1077",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Lost in the crowd

T2 - identifying targetable MHC class I neoepitopes for cancer immunotherapy

AU - Wilson, Eric A.

AU - Anderson, Karen

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Introduction: The recent development of checkpoint blockade immunotherapy for cancer has led to impressive clinical results across multiple tumor types. There is mounting evidence that immune recognition of tumor derived MHC class I (MHC-I) restricted epitopes bearing cancer specific mutations and alterations is a crucial mechanism in successfully triggering immune-mediated tumor rejection. Therapeutic targeting of these cancer specific epitopes (neoepitopes) is emerging as a promising opportunity for the generation of personalized cancer vaccines and adoptive T cell therapies. However, one major obstacle limiting the broader application of neoepitope based therapies is the difficulty of selecting highly immunogenic neoepitopes among the wide array of presented non-immunogenic HLA ligands derived from self-proteins. Areas covered: In this review, we present an overview of the MHC-I processing and presentation pathway, as well as highlight key areas that contribute to the complexity of the associated MHC-I peptidome. We cover recent technological advances that simplify and optimize the identification of targetable neoepitopes for cancer immunotherapeutic applications. Expert commentary: Recent advances in computational modeling, bioinformatics, and mass spectrometry are unlocking the underlying mechanisms governing antigen processing and presentation of tumor-derived neoepitopes.

AB - Introduction: The recent development of checkpoint blockade immunotherapy for cancer has led to impressive clinical results across multiple tumor types. There is mounting evidence that immune recognition of tumor derived MHC class I (MHC-I) restricted epitopes bearing cancer specific mutations and alterations is a crucial mechanism in successfully triggering immune-mediated tumor rejection. Therapeutic targeting of these cancer specific epitopes (neoepitopes) is emerging as a promising opportunity for the generation of personalized cancer vaccines and adoptive T cell therapies. However, one major obstacle limiting the broader application of neoepitope based therapies is the difficulty of selecting highly immunogenic neoepitopes among the wide array of presented non-immunogenic HLA ligands derived from self-proteins. Areas covered: In this review, we present an overview of the MHC-I processing and presentation pathway, as well as highlight key areas that contribute to the complexity of the associated MHC-I peptidome. We cover recent technological advances that simplify and optimize the identification of targetable neoepitopes for cancer immunotherapeutic applications. Expert commentary: Recent advances in computational modeling, bioinformatics, and mass spectrometry are unlocking the underlying mechanisms governing antigen processing and presentation of tumor-derived neoepitopes.

KW - antigen processing

KW - immunotherapy

KW - mass spectrometry

KW - MHC

KW - neoepitopes

KW - peptidome

KW - prediction algorithms

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=85057110158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057110158&partnerID=8YFLogxK

U2 - 10.1080/14789450.2018.1545578

DO - 10.1080/14789450.2018.1545578

M3 - Review article

VL - 15

SP - 1065

EP - 1077

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 12

ER -